HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer.

Abstract
In 2005, we initiated a clinical trial that examined the efficacy of the oncolytic virus HF10 to treat pancreatic cancer. Pancreatic cancer continues to have a high mortality rate, despite multimodal treatments for patients, and new therapeutic methods are greatly needed. The current mainstream methods for cancer treatment include biological therapeutics such as trastuzumab (Herceptin) for breast cancer or erlotinib (Tarceva) for non-small cell lung cancer. Oncolytic virus therapy is a new and promising treatment strategy for cancer. Oncolytic viruses are novel biological therapeutics for advanced cancer that appear to have a wide spectrum of anticancer activity with minimal human toxicity. To examine the efficacy of oncolytic virus therapy for pancreatic cancer, we initiated pilot studies by injecting six patients with non-resectable pancreatic cancer with three doses of HF10. All patients were monitored for 30 days for local and systemic adverse effects and were not administered any other therapeutics during this period. There were no adverse side-effects, and we observed some therapeutic potential based on tumor marker levels, survival, pathological findings and diagnostic radiography. The tumors were classified as stable disease in three patients, partial response in one patient and progressive disease in two patients.
AuthorsA Nakao, H Kasuya, T T Sahin, N Nomura, A Kanzaki, M Misawa, T Shirota, S Yamada, T Fujii, H Sugimoto, T Shikano, S Nomoto, S Takeda, Y Kodera, Y Nishiyama
JournalCancer gene therapy (Cancer Gene Ther) Vol. 18 Issue 3 Pg. 167-75 (Mar 2011) ISSN: 1476-5500 [Electronic] England
PMID21102422 (Publication Type: Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antigens, Neoplasm
  • Antigens, Viral
  • CA-19-9 Antigen
  • DU-PAN-2 antigen, human
Topics
  • Aged
  • Antigens, Neoplasm (blood)
  • Antigens, Viral (metabolism)
  • CA-19-9 Antigen (blood)
  • CD4-Positive T-Lymphocytes (metabolism)
  • CD8-Positive T-Lymphocytes (metabolism)
  • Carcinoma, Pancreatic Ductal (diagnostic imaging, pathology, therapy)
  • Humans
  • Injections
  • Macrophages (metabolism)
  • Male
  • Middle Aged
  • Oncolytic Virotherapy
  • Oncolytic Viruses (genetics, metabolism)
  • Pancreatic Neoplasms (diagnostic imaging, pathology, therapy)
  • Radiography
  • Radionuclide Imaging
  • Simplexvirus (genetics, metabolism)
  • Survival Analysis
  • Treatment Outcome
  • Watchful Waiting

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: